Delivery Order SPE2DB22D2007-SPE2DB25FJ4DK
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Qulipta 60 mg tablets in a quantity of 30 units, valued at $7,459.83. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and was awarded on July 29, 2025, with an ultimate completion date of July 30, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Qulipta 60 mg tablets (30-count packages) under a firm fixed-price contract valued at $1,649.05. The award, issued on August 8, 2025, with an ultimate completion date of August 11, 2025, represents a non-competitive delivery order without set-aside designation. AmerisourceBergen will perform this contract from its corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $3,372.82 delivery order to AmerisourceBergen Drug Corp for Qulipta 60 mg tablets (30-count units) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed price contract represents a non-competitive set-aside delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be performed at the vendor's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $13,955.02 to AmerisourceBergen Drug Corp for 30-count tablets of Qulipta 60 mg, a pharmaceutical product used in neurological treatment applications. The contract is a firm fixed price delivery order with an ultimate completion date of August 18, 2025, and was awarded on August 15, 2025. No set-aside designation was used for this competitive award. Performance will occur at AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,373.74 to AmerisourceBergen Drug Corp for the supply of Qulipta 60 mg tablets (30-count package) on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at the contractor's location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical supply transaction under the DLA's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Qulipta 60 mg tablets (quantity: 30 units) valued at $7,886.20. This firm fixed-price delivery order, which will be completed by July 31, 2025, represents a non-competitive award under the contractor's existing Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken,...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $2,694.51, is for the delivery of 4,568,104,420 units of the medication Qulipta 60 mg tablet. The contract has a firm fixed price and is not a set-aside procurement. It has an ultimate completion date of May 22, 2025. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,154.79, is for the supply of Qulipta 60 mg tablets, a neurological medication. The award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support vehicle to the Defense Health...
- This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the medication Qulipta 60 mg tablet. The delivery order has a ceiling value of $1,539.72 and is a firm fixed-price contract with a completion date of May 23, 2025. The contract is not set aside and is an open competition award. AmerisourceBergen Drug Corp is the prime contractor and holds a larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Qulipta 60 mg tablets (30-count packages) under a firm fixed-price contract. The order, valued at $2,400.59, represents a competitive award with no set-aside designation and a completion deadline of July 28, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ4DKDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,488.21 to AmerisourceBergen Drug Corp for Qulipta 60 mg tablets (30-unit supply) on August 20, 2025, with an ultimate completion date of August 21, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Qulipta is a psychiatric medication used in the treatment of bipolar disorder and other mental health conditions, reflecting the Defense Logistics Agency's ongoing commitment to supplying pharmaceutical products for military healthcare systems. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a comprehensive $999.999 billion global pharmaceutical support vehicle valued through December 2026. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen has demonstrated substantial capability in fulfilling diverse pharmaceutical supply requirements across multiple therapeutic domains for military and veteran healthcare systems. The company's role as a prime vendor for DLA reflects its strategic importance in supporting the Defense Health Agency and other government healthcare operations worldwide through flexible contract mechanisms designed to meet dynamic military medical supply demands.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.5k | 8/20/25 |